AccuGenomics Provides an AccuKit to Qura Therapeutics as Part of a Research Collaboration Agreement

AccuKit-HIV utilizes AccuGenomics’ Standardized Nucleic Acid Quantification (SNAQ) technology and standardized molecular testing kit WILMINGTON, NC, August 15, 2017 – AccuGenomics, Inc., a diagnostic company based in Wilmington, NC, today announced that the company has provided an AccuKit to the HIV Cure Center at the University of North Carolina at Chapel Hill and to Qura…

SNAQ BCR-ABL Pilot Study Results Presented at 20th Annual European Hematology Association Meeting.

Wilmington, NC. June 2015. MD Anderson presented results of the SNAQ BCR-ABL pilot study conducted with MD Anderson at the 20th European Hematology Conference. The molecular tests for measuring of Philadelphia chromosome blood abundance has proven to be an invaluable tool for monitoring CML treatment. However, despite intense international efforts to control for process variation…

Partnering with Nuclea Biotechnologies on BCRABL development

Wilmington, NC. January 1 2014. AccuGenomics, Inc. has licensed   its standardized BCRABL test to Nuclea Biotechnologies, Inc., for the treatment of Chronic Myeloid Leukemia. Nuclea will offer the BCRABL test in its CLIA laboratories and manufacture the BCRABL kits for the Northeast market. The agreement with Nuclea Biotechnologies will soon lead to more effective treatments…

Accugenomics has received exclusive licences on STARSEQ technology from University of Toledo.

Wilmington , NC. April 7 2014. Accugenomics and The Uuniversity of Toledo have finalized a exclusive license agreement that provides Accugenomics worldwide rights to commercialize STARSEQ™ Technology. STARSEQ technology will fulfill a next generation sequencing need to run at very low cost, quality controlled and reproducible multigene transcript abundance analysis in large numbers of samples…

News

See our latest publications here.

[catlist name=”press”+”news” date=yes]